Where Immunovant Stands With Analysts
Portfolio Pulse from Benzinga Insights
Immunovant (NASDAQ:IMVT) has received positive ratings from analysts in the last quarter, with 6 bullish and 7 somewhat bullish ratings, and no bearish sentiments. The average 12-month price target for IMVT is $41.69, with a high of $57.00 and a low of $30.00. This target has increased by 45.21% over the past month, indicating a positive outlook from analysts.
November 15, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant has received a strong vote of confidence from analysts with 13 positive ratings and an increased average price target of $41.69, suggesting a bullish outlook for the stock.
The unanimous positive ratings from analysts and the significant increase in the average price target over the past month are strong indicators of a bullish sentiment towards IMVT. This consensus could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100